Chemcon Speciality Chemicals IPO Review, Issue Details

Incorporated in 1988, Chemcon Speciality Chemicals Ltd is a maker of specific chemical items i.e. HMDS and CMIC. Its product portfolio consists of oilfield chemicals (Calcium Bromide, Sodium Bromide, and Zinc Bromide), Pharma intermediates, Silanes, and chemical contract production work. The post is about Chemcon Speciality Chemicals IPO Review.

Chemcon Speciality Chemicals Issue Details

For the Draft Red Herring Prospectus or DRHP CLICK HERE.

First Day–.

Business are a manufacturer of specialised chemicals, such as HMDS and CMIC which are mainly used in the pharmaceuticals industry (the “Pharmaceutical Chemicals”), and inorganic bromides, particularly Calcium Bromide, Zinc Bromide and Sodium Bromide, which are mainly utilized as completion fluids in the oilfields market( the “Oilwell Completion Chemicals”).

From FY 2016-17 to FY 2018-19, according to the Restated Financial Statements.

While doing the Chemcon Speciality Chemicals IPO Review, knowing about the business is necessary. Chemcon Chemicals is a leading producer of Pharmaceutical chemicals and creates optimum income from this specific sector.

Listing At.

Chemcon Limited IPO Date.

Issue Open: September 21, 2020.
Issue Close: September 23, 2020.
Minimum Investment Amount: Rs. 14960/-.
Cost Band: Rs. 338/- to Rs. 340/-.
Face Value: Rs. 10/-.
Quote Lot Size: 44 and in multiples of it thereafter.

Issue Type
Book Built Issue IPO

Chemcon Speciality ChemicalsSummary of Chemcon IPO.

For Fiscals 2019, 2018 and 2017, our profits from operations was Rs.3,041.68 million, Rs.1,583.07 million and Rs.898.92 million, respectively, growing at a CAGR of 83.95% between Fiscal 2017 and Fiscal 2019.

The business is not only serves the domestic market however also exports its items in the overseas market. The abroad market includes USA, China, Japan, UAE, Serbia, Russia, Malaysia, and Azerbaijan. It has a factory at Manjusar near Vadodara in Gujarat, 5 operational plants, 3 storage facilities, and 2 rented warehouses.

Day/ Date.
Overall Subscription.

About the Company.

IPO Date

Face Value.
10 per equity share.

Our EBITDA for Fiscals 2019, 2018 and 2017 was Rs.679.21 million, Rs.456.81 million and Rs.86.60 million respectively, growing at a CAGR of 180.06% in between Fiscal 2017 and Fiscal 2019, while our revenue after tax for Fiscals 2019, 2018 and 2017 was Rs.430.41 million, Rs.263.81 million and Rs.28.24 million respectively, growing at a CAGR of 290.39% between Fiscal 2017 and Fiscal 2019.

The Promoters of this business are KAMALKUMAR RAJENDRA AGGARWAL, NAVDEEP NARESH GOYAL AND SHUBHARANGANA GOYAL. The lead manager to the issue are Intensive Fiscal Services Private Limitedand Ambit Capital Private Limited & & the Registrar to this issue is Link Intime India Private Limited.

The essential clients of Pharmaceutical Chemicals consist of Hetero Labs Limited, Laurus Labs Limited, Aurobindo Pharma Limited, Sanjay Chemicals (India) Private Limited, Lantech Pharmaceuticals Limited, Ind- Swift Laboratories Limited, Vivin Drugs & & Pharmaceuticals Limited, Macleods Pharmaceuticals Limited and thekey customers of Oilwell Completion Chemicals consist of Shree Radha Overseas, Water Systems SpecialtyChemical DMCC, Universal Drilling Fluids and CC Gran Limited Liability Company.

Min Order Quantity.
1 Lot.

Deal for Sale.
4,300,000 Eq Shares of 10( aggregating up to [] Cr).

Chemcon IPO Subscription.

Concern Size

Fresh Issue
[] Eq Shares of 10( aggregating approximately 175.00 Cr).

IPO Price.
[] to [] per equity share. Market Lot.

2nd Day–.

3rd Day–.

Fourth Day–.

5th Day–.

The stated value of each share is Rs 10, and the cost band of the IPO is Rs. 338/- to Rs. 340/-.

Chemcon Limited– Company Overview.

Here, you can discover the Allotment Status of this IPO.

On the basis of Standalone statement:-.

Consequently, Company was transformed into a public restricted business pursuant to the approval of Shareholders at an amazing basic meeting hung on November 28, 2018.

A peek into the past monetary performance of the company to understand its performance of company and assess the development prospectus:.

Shares Offered or Net Issue.

Promoters and Promoter Group finished the acquisition of 100% of the Equity Share capital of our Company in 2004 from the shareholders of our Company at the time.

Equity Shares of face value of Rs.10/- each for money at a rate of Rs. Millions.

Expansion of our total installed production capability.
Augmenting development in the current geographical markets and broadening into new geographic markets.
Checking out more recent applications of our existing products along with concentrating on new items that are in synergywith our present operations.
Continue to pursue expense effectiveness.

Chemcon IPO Allotment Status.

Consequently, the name of Company was altered to “Chemcon Speciality Chemicals Limited” and a Fresh certificate of incorporation consequent upon conversion to public restricted business was provided by the RoC on April 10, 2019.

Chemcon Speciality Chemicals Limited– Financial Statements.

Financial Summary of Chemcon Speciality Chemicals.

The shares subscribed by the public will be upgraded herein every day, when the IPO is open for membership.

Chemcon IPO Equity Share Offering.

Business was originally included as Gujarat Quinone Private Limited at Vadodara, Gujarat, India, as a personal minimal company under the Companies Act, 1956, pursuant to a certificate of incorporation dated December 15, 1988 released by the RoC.

Company methods of Chemcon Limited.

Chemcon IPO Price Band.

Amount (in INR & & Millions)


Overall Assets. 1,310.91.
654.81. 365.93.

Incomes per Equity Share (in Millions).

Overall Expense.

Profit After Tax.

Overall Revenue.


Business Promoters:.

List of Related Parties (Key Managerial Personnel).

Chemcon IPO– Basis of the Offer Price.

Approximately [●] Equity Shares, aggregating up to Rs [●] million. Of which:.

We are a leading manufacturer globally of the Pharmaceutical Chemicals and we are a leading manufacturerin India of the Oilwell Completion Chemicals (Source: Frost & & Sullivan Report);.
Diversified customer base coupled with long standing relationships;.
The specialized chemicals industry in which we run has high entry barriers;.
Constant financial performance with a strong monetary position;.
Manufacturing facility with dedicated plants for each of our products; and.
Experienced senior management.

As on the date of filing of the Draft Red Herring Prospectus, the Company does not own any copyright rights.

Equity Shares impressive prior to the Issue.
31,777,760 Equity Shares.

Essentially, the company has a moderate to strong fundamental base. After talking about the business profile, it is time to concentrate on the competitive strength.

Promoters have an interest in the Company to the level that they are the Promoters of Company and to theextent of their respective shareholding in Company, their directorship in Company and the dividendspayable, if any, and any other circulations in regard of their particular shareholding in Company or theshareholding of their relatives in Company.

Firm functions to make use of the net profits from the IPO towards the below goals. From these goals, you will get a clear idea of the reason for issuing the shares.

Shahilkumar Maheshbhai Kapatel, Company Secretary and Compliance Officer.
Rajesh Chimanlal Gandhi, Chief Financial Officer.

Chemcon IPO– Promoters.

From the above declarations, one might find that Chemcon Limited might perform well.

For the year/period ended (in million).

Net Issue to the Public.
Approximately 4,300,000 Equity Shares, aggregating up toRs [●] million.

Competitive strengths.

Here, is the details of business financials.

Of which:.


Standard & & Diluted.

Reserved for Market Makers.
As much as [●] Equity Shares, aggregating approximately Rs1,750 million.

These are the IPO Issue Objects of the company.

Chemcon Limited IPO Issue Object.

The Promoter of this company is:.

Equity Shares exceptional after the Issue.
Upto [●] Equity Shares.

Chemcon Limited IPO Offer Details or Issue Details.

Capital investment towards expansion of our Manufacturing Facility (” Project”);.
To fulfill working capital requirements; and.
General corporate functions.

No. Of Equity Shares.

Interest in promotion of the Company.

Retail Investors Portion.
Not less than [●] Equity Shares.

Company Financials:.

KamalKumar Rajendra Aggarwal, Navdeep Naresh Goyal, and Shubharangana Goyal are the promoters of the company.

Qualitative factors are:.

The issue cost is figured out by the company in consultation with the Lead supervisor on the basis of the following qualitative and quantitative elements.

Equity Shares Offered.

Objects of the Issue:.

Non-Retail Investors Portion.
Not less than [●] Equity Shares.

– Largest manufacturer of pharmaceutical chemicals across the world – Leading oilfield chemicals maker in India. – Diversified customers base in the global and domestic markets. – Strong and consistent financial efficiency. – Dedicated factory for each product.

Interest in Intellectual Rights of the Company.

Home Interest.

Promoters do not have any interest in any endeavor that is involved in any activities comparable to those conductedby Company.



The post is about Chemcon Speciality Chemicals IPO Review.

As you can see in the company financials. While doing the Chemcon Speciality Chemicals IPO Review, based on the above information and the company financials, we likewise keep a SUBSCRIBE ranking on the concern. Make sure you inspect the IPO at the last day of applying with our special monitoring method.

Earnings After Tax.

While doing the Chemcon Speciality Chemicals IPO Review, understanding about the company is required. The company is not only serves the domestic market but likewise exports its items in the overseas market. As you can see in the business financials. While doing the Chemcon Speciality Chemicals IPO Review, based on the above information and the company financials, we likewise keep a SUBSCRIBE score on the problem.

Total Assets.

Total Revenue.

Chemcon Speciality Chemicals IPO Review.